Medical leaders across Africa are crafting specific rules for Helicobacter pylori to combat ulcers and cancer. According to Punch, the African Helicobacter and Microbiota Study Group (AHMSG) is leading this effort. The group aims to tackle stomach infections by creating protocols that fit local realities. These realities include scarce funding, limited clinic access, and weak diagnostic tools. Existing international standards often fail to address these distinct socioeconomic barriers. The initiative seeks to reduce the heavy burden of gastric cancer and related diseases on the continent.

The AHMSG will present these plans at its second International Scientific Conference. This event is scheduled for November 27 and 28, 2026, in Lusaka, Zambia. The Grand Palace Hotel will host the two-day gathering. International specialists will join local experts to discuss emerging research. Professor Emeritus Colm O’Morain from Trinity College Dublin will deliver the keynote address. His speech will focus on future opportunities and challenges in H. pylori research over the next four decades.

Professor Yoshio Yamaoka, a specialist in gastric cancer pathogens, will also speak. He will discuss collaborative research progress in Africa. AHMSG President Professor Mashiko Setshedi stated that the program includes panel discussions and awards. Goodwill messages are expected from Professor Peter Malfertheiner of ZAGAN and Professor Kelly. The agenda also features the AHMSG presidential handover and board meetings. These sessions aim to advance the group’s strategic goals for the coming year.

The study group launched in Lagos, Nigeria, in 2022. Professor Stella Smith of the Nigerian Institute of Medical Research founded the organization. She noted that global guidelines ignored Africa’s unique healthcare constraints. Initial members came from Nigeria, South Africa, Cameroon, Egypt, Kenya, Morocco, Senegal, and Tanzania. The network has since grown to include Zambia, Namibia, and the Democratic Republic of Congo.

Richen Medical Sciences, a Chinese technology firm, provides major sponsorship. Dr Attilio Citrino, the company’s global marketing director, said the support reflects a commitment to scientific partnerships. He emphasized that innovation must reach patients to have value. The Beijing-based company develops non-invasive diagnostic tools for gastrointestinal disorders. It aims to strengthen ties with African institutions to improve early disease detection.